EBS Earnings Date: Nov 2, 2026 (Estimated) — Emergent BioSolutions Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is EBS's next earnings date?
Emergent BioSolutions Inc. (EBS) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.37 on revenue of $123.2M.
How did EBS do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Emergent BioSolutions Inc. posted EPS of $0.60 versus the -$0.09 estimate, a beat of 445.5%. Revenue was $234.3M against a $177.5M estimate. The stock's 1-day post-earnings move was -29.6%.
How much does EBS stock move after earnings?
EBS beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 25.0% (up or down) in the day after earnings.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.09 | 0.60 | +445.45% | $234.3M | ✅ Beat | -29.58% | -39.66% | -17.37% |
| 2026-04-30 | Q1 2026 | -0.25 | 0.21 | +184.00% | $156.1M | ✅ Beat | +2.92% | +10.94% | +3.16% |
| 2026-02-26 | Q4 2025 | 0.32 | -0.43 | -234.38% | $148.7M | ❌ Miss | -26.58% | -23.96% | -28.56% |
| 2025-10-29 | Q3 2025 | -0.03 | 1.06 | +3633.33% | $231.1M | ✅ Beat | +36.60% | +10.00% | +18.83% |
| 2025-08-06 | Q2 2025 | -0.40 | 0.16 | +140.00% | $140.9M | ✅ Beat | +36.65% | +45.77% | +25.70% |
| 2025-03-03 | Q4 2024 | -0.50 | 0.05 | +110.00% | $194.7M | ✅ Beat | -6.44% | -17.72% | -30.60% |
| 2024-11-06 | Q3 2024 | 0.14 | 1.37 | +878.57% | $293.8M | ✅ Beat | +19.57% | +8.37% | -2.07% |
| 2024-08-06 | Q2 2024 | -0.94 | -2.32 | -146.81% | $254.7M | ❌ Miss | -41.99% | -31.24% | -22.62% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $234.3M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 96.8% | $226.8M | +74.1% | $269.5M | $181.9M | $209.1M | $130.3M |
| Contracts and Grants | 3.2% | $7.5M | -29.2% | $10.0M | $5.4M | $13.1M | $10.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.